1236278-28-6

1236278-28-6 structure

Name: Clazakizumab
Chemical Name: Clazakizumab
CAS Number: 1236278-28-6
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Anti-infection SARS-CoV
Create Date: 2022-08-18 10:52:12
Modify Date: 2024-09-17 10:41:48
Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection[1][2].

Name	Clazakizumab

Description	Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection[1][2].
Related Catalog	Research Areas >> Infection Signaling Pathways >> Immunology/Inflammation >> Interleukin Related Signaling Pathways >> Anti-infection >> SARS-CoV Research Areas >> Inflammation/Immunology
Target	IL-6
References	[1]. Mease PJ, et al. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis. Arthritis Rheumatol. 2016 Sep;68(9):2163-73. [2]. Vaidya G, et al. Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report. Transplant Proc. 2020 Nov;52(9):2711-2714.

No Any Chemical & Physical Properties